Scandion Oncology
Overcoming cancer drug resistance

Navbar

About us
Research & Development
Press releases
Investors & Media
Contact
- Career
- Business development

Skip to content

Aktiespararna

Watch Chief Operating Officer Maj Hedtjärn present Scandion at Aktiespararna Småbolagsdagarna 2022

Post navigation

Redeye Transactions

Frontpage
Press releases
Aktiespararna

About us

About us
Executive Management
Board of Directors
Clinical Advisory Board

Research & Development

Research & Development
Pipeline
Clinical Development
Science

Investors & Media

Investors & Media
Share information
Financial Reports
Presentations
Media
Analyst Coverage
Prospectuses
Corporate governance
Events

Contact us

Scandion Oncology A/S
Symbion
Fruebjergvej 3
2100 Copenhagen
Denmark

Phone: +45 38 10 20 17
info@scandiononcology.com

Media and Investor relations:
Email: ir@scandiononcology.com
Phone: +45 29 60 35 32

Follow us

Scandion Oncology - The Cancer Drug Resistance Company

Our vision is to overcome cancer drug resistance in order to improve lives for cancer patients and their families

© Copyright 2022 - Scandion Oncology A/S | We use cookies to improve our services | Disclaimer: Market data could be delayed. Delivered by Cision.